Docket No.: FLGDK29.002APC

COMMUNICATION REGARDING CERTIFICATE OF CORRECTION

Applicant : Giannotta et al...

App. No : 10/589,233

Filed: January 16, 2007

Patent No. : 7,745,193

Issued : June 29, 2010

For : HYBRID PROTEINS OF ACTIVE-

SITE SERINE BETA LACTAMASE

Examiner : Raghu, Ganapathiram

Art Unit : 1652

Conf # : 4530

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Dear Sir,

Enclosed for filing is a Certificate of Correction in connection with the above-identified patent.

As some of the errors cited in the Certificate of Correction were incurred through the fault of the Applicant, fees in the amount of \$100 are paid herewith according to 37 C.F.R. § 1.20(a).

With regard to the error at column 4, line 30, Applicant's Preliminary Amendment dated August 10, 2006 amended paragraph [0017], but did not include the full identifier for SEQ ID NO: 47. Moreover, the deletion of text after the amino acid sequence designated SEQ ID NO: 47 was unintended. The original paragraph stated with regard to the sequences designated as SEQ ID NO: 46 and SEQ ID NO: 47: "...respectively, in AmpC, and defined by alpha helices which correspond to those in β -lactamases of the same class or of classes A and D." The Applicant respectfully requests restoration of this original language in reference to SEQ ID NO: 46 and SEQ ID NO: 47.

Please charge any additional fees to our Deposit Account No. 11-1410.

Respectfully submitted,

KNOBBE, MARTENS, OLSON & BEAR, LLP

Dated: December 1, 2010 By: /Raymond D. Smith/

Raymond D. Smith Registration No. 55,634 Agent of Record Customer No. 20,995 (949) 760-0404

UNITED STATES PATENT AND TRADEMARK OFFICE CERTIFICATE OF CORRECTION

PATENT NO. : 7,745,193 Page 1 of 2

APPLICATION NO. : 10/589,233
ISSUE DATE : June 29, 2010
INVENTOR(S) : Giannotta et al.

It is certified that error appears in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

At the Face Page, (Item 56) right column, line 11, please delete "eta l.," and insert therefore, --et al.,--.

At the Face Page, (Item 56) right column, line 16, please delete "virua-1," and insert therefore, --virus-1,--.

At the Face Page, (Item 56) right column, line 33, please delete "Curent" and insert therefore, --Current--.

At Drawing Sheet 14 of 21 (Figure 14 A B C D), please delete "14 A B C D" and insert therefore, --14 A, B, C, D--.

At column 1, line 32, please delete "1345-58.)" and insert therefore, --1345-58)--.

At column 4, line 30 (approx), please delete "47." and insert therefore, --47) respectively, in AmpC, and defined by alpha helices which correspond to those in β-lactamases of the same class or of classes A and D.--.

At column 6, line 56, please delete "β-lactamase" and insert therefore, --(β-lactamase--.

At column 8, line 37, please delete "Sural)" and insert therefore, --SmaI)--.

At column 8, line 39, please delete "hPLA2" and insert therefore, --hPLA2--.

At column 9, line 67, please delete "TEM- β " and insert therefore, --TEM-1 β --.

At column 13, line 27, please delete "Influenca" and insert therefore, --Influenza---.

At column 14, line 35, please delete "TEM-1 Gβ" and insert therefore, --TEM-1 β--.

At column 15, line 18, please delete "homolgous" and insert therefore, --homologous--.

At column 16, line 21 (approx), please delete "tested:" and insert therefore, --tested:--.

At column 16, line 57, please delete "potentimetric" and insert therefore, --potentiometric--.

At column 17, line 2, please delete "thyphimurium," and insert therefore, --typhimurium--.

At column 18, line 14, please delete "is" and insert therefore, --it--.

At column 19, line 15 (approx), please delete "hydrids" and insert therefore, --hybrids--.

At column 19, line 30, please delete "glutathion-5-transferase" and insert therefore, --glutathione-S-transferase--.

At column 19, line 40, please delete "Beta-lactamase" and insert therefore, --β-lactamase--.

At column 20, line 28, please delete "anti-Sta" and insert therefore, --anti-STa--.

At column 20, line 51, please delete "t a" and insert therefore, --to a--.

At column 21, line 55, please delete "I/c" and insert therefore, --I/C--.

At column 21, line 63, please delete "197Sta" and insert therefore, --197STa--.

At column 22, line 7 (approx), please delete "I/c" and insert therefore, --I/C--.

At column 24, line 55, please delete "P" and insert therefore, --β--.

At column 26, line 10, please delete "peroxydase," and insert therefore, --peroxidase,--.

At column 29, line 41, please delete "peroxydase" and insert therefore, --peroxidase--.

MAILING ADDRESS OF SENDER:

Raymond D. Smith KNOBBE, MARTENS, OLSON & BEAR, LLP 2040 Main Street, 14th Floor Irvine, California 92614

DOCKET NO. FLGDK29.002APC

UNITED STATES PATENT AND TRADEMARK OFFICE CERTIFICATE OF CORRECTION

PATENT NO. : 7,745,193 Page 2 of 2

APPLICATION NO. : 10/589,233

ISSUE DATE : June 29, 2010

INVENTOR(S) : Giannotta et al.

At column 30, line 12 (approx), please delete "protein" and insert therefore, --protein protein--.

At column 30, line 25, please delete "88(34)" and insert therefore, --88(3-4)--.

At column 30, line 37, please delete "92" and insert therefore, --92.--. At column 30, line 41, please delete "32" and insert therefore, --32.--.

At column 30, line 46 (approx), please delete "293" and insert therefore, --293-6.--.

At column 30, line 52, please delete "Sherraft" and insert therefore, --Sherratt--.

At column 30, line 55 (approx), please delete "7;" and insert therefore, --7.--.

At column 30, line 60, please delete "818" and insert therefore, --818.--.

At column 68, line 5 in Claim 12, please delete "β-lactamase" and insert therefore, --(β-lactamase--.

10083687 113010

MAILING ADDRESS OF SENDER:

Raymond D. Smith KNOBBE, MARTENS, OLSON & BEAR, LLP 2040 Main Street, 14th Floor Irvine, California 92614

DOCKET NO. FLGDK29.002APC